Ultragenyx Pharmaceutical (RARE) Other Working Capital Changes (2013 - 2024)

Ultragenyx Pharmaceutical (RARE) has 12 years of Other Working Capital Changes data on file, last reported at -$12.7 million in Q3 2024.

• On a quarterly basis, Other Working Capital Changes fell 154.87% year-over-year to -$12.7 million in Q3 2024; TTM through Sep 2024 was -$11.0 million, a 44.46% increase from a year earlier, with the FY2023 full-year figure at -$15.3 million, down 303.5% from the prior year.
• Other Working Capital Changes for Q3 2024 stood at -$12.7 million, down from $7.0 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for RARE reached as high as $22.5 million in Q4 2021 and fell as low as -$15.2 million in Q4 2020.
• Historically, Other Working Capital Changes has averaged -$243789.5 across 5 years, with a median of -$2.0 million in 2021.
• Across the five-year window, Other Working Capital Changes jumped 1062.45% in 2022 and sank 1362.62% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at -$15.2 million in 2020, then soared by 248.13% to $22.5 million in 2021, then slumped by 114.38% to -$3.2 million in 2022, then surged by 138.86% to $1.3 million in 2023, then tumbled by 1110.17% to -$12.7 million in 2024.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were -$12.7 million in Q3 2024, $7.0 million in Q2 2024, and -$6.6 million in Q1 2024.